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ABSTRACT
Weight loss has been proposed as a sign of pre-clinical Alzheimer Disease (AD). 
To test this hypothesis, we have evaluated the association between longitudinal 
changes in weight trajectories, cognitive performance, AD biomarker profiles and 
brain structure in 363 healthy controls from the Alzheimer´s Disease Neuroimaging 
Initiative (mean follow-up 50.5±30.5 months). Subjects were classified according to 
body weight trajectory into a weight loss group (WLG; relative weight loss ≥ 5%) and 
a non-weight loss group (non-WLG; relative weight loss < 5%). Linear mixed effects 
models were used to estimate the effect of body weight changes on ADAS-Cognitive 
score across time. Baseline CSF tau/Aß42 ratio and AV45 PET uptake were compared 
between WLG and non-WLG by analysis of covariance. Atrophy maps were compared 
between groups at baseline and longitudinally at a 2-year follow-up using Freesurfer. 
WLG showed increased baseline levels of cerebrospinal fluid tau/Aß42 ratio, increased 
PET amyloid uptake and diminished cortical thickness at baseline. WLG also showed 
faster cognitive decline and faster longitudinal atrophy. Our data support weight loss 
as a non-cognitive manifestation of pre-clinical AD.
     Research Paper: Gerotarget (Focus on Aging)
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INTRODUCTION
Unintentional weight loss in elderly subjects has 
been related to disability and increased mortality [1, 2]. 
Dementia is a major cause of disability and mortality in 
the elderly, and has also been associated with weight loss 
[3-5]. Moreover, dementia severity correlates with weight 
loss and malnutrition [3]. This weight loss in the context 
of dementia could be explained by a lower energy intake 
due to significant neuropsychological symptoms related to 
disease progression.
Several epidemiological studies, nonetheless, 
have also identified weight loss preceding the onset of 
dementia [6-11], and recently published epidemiological 
data have consistently shown that weight loss may precede 
mild cognitive impairment (MCI) [7, 12, 13]. This last 
observation suggests that weight loss could be a non-
cognitive sign of preclinical Alzheimer’s Disease (AD). 
According to NIA-AA criteria, preclinical AD is defined 
by evidence of brain amyloidosis through biomarkers [14] 
(labeled as asymptomatic at-risk in the IWG lexicon [15]). 
However, there is a lack of published multimodal studies 
assessing the relationship between weight loss, cognition, 
AD biomarkers and brain structure in the healthy elderly.
We hypothesized that weight loss in elderly subjects 
is a non-cognitive sign of preclinical AD that could predict 
cognitive decline and would be associated with brain 
atrophy and AD biomarkers. In this longitudinal study, we 
aimed to examine (1) changes on cognitive performance 
over time, (2) the baseline AD biomarker profile and (3) 
cross-sectional and longitudinal brain structural changes 
according to body weight trajectories in healthy controls 
from the Alzheimer´s Disease Neuroimaging Initiative 
(ADNI).
RESULTS
Three hundred and sixty three subjects were 
included in the study (Figure 1). The mean age was 
74.9±5.8 years, 189 were female, and the mean baseline 
BMI was 26.9±4.0 Kg/m2. At a mean follow-up of 
50.5±30.5 months (range: 12 to 120 months), the mean 
weight change for the whole cohort was -2.2±6.3% 
of baseline body weight (range: -23.1% to +19.1%). 
Eighty nine of the 363 subjects (24.5%) lost ≥5% of 
total body weight. Table 1 summarizes the demographic, 
anthropometric and neuropsychological data at baseline 
according to the weight loss trajectory. The WLG had a 
slightly higher baseline BMI than the non-WLG. No other 
significant differences were found at baseline evaluation 
between both groups. Follow-up was longer in the WLG 
than in the non-WLG group (45.0±28.0 months vs. 
64.2±33.1 months, p < 0.001).
Weight loss is associated with faster cognitive 
decline
A total of 2,051 observations were used in the 
linear mixed effects analysis including follow-up of the 
363 subjects. Linear mixed effects analyses showed a 
significant interaction between time and body weight 
changes on the ADAS-Cog both when analyzing weight 
changes as categorical and when analyzing weight 
Figure 1: Flowchart showing the samples used in this work and the subsets utilized for analyses.
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changes as a continuous variable. WLG showed a mean 
(SEM) increase of 0.57 (0.15) ADAS-Cog points more 
per year than the non-WLG (p < 0.001). Higher relative 
weight loss was also associated with a faster cognitive 
decline (p < 0.01) when treated continuously (Table 2). 
The inclusion of baseline BMI or T2D status as covariates 
did not change the results. 
Figure 2 displays the unadjusted mean ADAS-Cog 
score and their corresponding standard error of mean 
according to the WL categories at each follow-up visit.
Weight loss is associated with AD biomarkers in 
the healthy elderly
Two hundred and seventy three study participants 
had available baseline CSF or AV45 PET data. Subjects 
with baseline CSF or AV45 PET data were younger than 
the rest of participants (74.4±6.1 vs. 76.1±4.9 years, p 
= 0.006). No other significant differences were found 
between this subset and the whole cohort (Supplementary 
Table 1).
Demographic, anthropometric and 
neuropsychological data at baseline according to weight 
trajectories in the AD-biomarkers subset are presented 
in Table 1. No significant differences between WLG and 
non-WLG were found at baseline evaluation.
In the ANCOVA analysis, after adjustment for age, 
sex and APOE genotype, WLG showed higher baseline 
AV45 PET SUVR (1.179±0.248 vs. 1.098±0.159; p = 
0.020) and higher CSF total tau/Aß42 ratio (0.454± 0.319 
vs. 0.355±0.224, p = 0.005) compared to non-WLG. 
Inclusion of baseline BMI or T2D status as covariates did 
Table 1: Demographic, anthropometric and neuropsychological data at baseline according to the weight trajectories for whole cohort and PET-
AV45, CSF and MRI subsets.
WLG: weight loss group; non-WLG: non weight loss group. CSF: cerebrospinal fluid; MRI: magnetic resonance image; BMI: body mass index, SBP: systolic 
blood pressure, DBP: diastolic blood pressure, FPG: fasting plasmatic glucose, T2D: type 2 diabetes, MMSE: minimental score examination, ADAS-Cog: 
Alzheimer’s Disease Scale Assessment.,*: p<0.05,
Table 2: Multivariable Mixed-Effects Linear Models for Alzheimer’s Disease Scale Assessment scores. 
ADAS-Cog: Alzheimer’s Disease Scale Assessment scores. a: Adjusted for age, sex and time.
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not significantly change the association between weight 
trajectories and CSF total tau/Aß42 ratio (p = 0.005 and p 
= 0.005, respectively) or between weight trajectories and 
AV45 PET SUVR (p = 0.020 and p = 0.019, respectively). 
Exclusion of subjects that progressed to MCI 
or dementia in the follow-up (n = 49) did not change 
association between weight loss and total tau/Aß42 ratio 
(0.33± 0.21 vs. 0.44±0.32, p = 0.01) or between weight 
loss and AV45 PET SUVR (1.091±0.156 vs. 1.182±0.252; 
p = 0.016).
In the linear regression analyses we observed 
similar results. There was a trend for a positive correlation 
between weight loss levels and baseline t-tau/Aß42 ratio (p 
= 0.077) and a significant association between weight loss 
levels and baseline AV45 uptake (p = 0.022).
Weight loss is associated with baseline cortical 
thinning and accelerated atrophy rates
Table 1 shows the clinical characteristics of the 
study participants with available MRI at baseline and 
2-years follow-up. There were no significant differences 
between this subset (nor the longitudinal MRI subset) and 
the whole cohort (Supplementary Table 2).
MRI results are presented in Figure 3. At baseline, 
the WLG presented cortical thinning in temporal regions 
of the right hemisphere (Figure 3A) with respect to the 
non-WLG. Subjects in the WLG also showed accelerated 
atrophy rates with respect to the non- WLG in widespread 
areas of both hemispheres (Figure 3B). Neither adjustment 
for AD biomarkers nor inclusion of T2D or baseline 
BMI as covariates significantly altered the results (data 
not shown). The boxplots illustrate the median CTh and 
spc for each group and the respective upper and lower 
quartiles (Figures 3A2 and 3B2).
No significant differences were found in CTh 
between the WLG and the non-WLG when subjects that 
progressed to MCI or dementia were exluded. In the 
longitudinal analysis, the WLG showed several clusters of 
accelerated cortical thinning in the precuneus and frontal 
superior areas of both hemispheres (FWE p < 0.05) when 
compared to the non-WLG (Supplementary Figure 1).
In the correlation analyses weight loss was 
associated with cortical thinning in the same areas 
identified in the group comparison analyses. No significant 
correlations between relative weight change and spc were 
found (Supplementary Figure 2).
Figure 2: Observed means (SEM) differences in Alzheimer’s Disease Scale Assessment. Scores according to body weight 
trajectory groups. In blue is represented the ADAS-Cog trajectory for the non-WLG throughout time and in red is represented the ADAS-
Cog trajectory for the WLG throughout time. Dots represent mean of each time-point for both groups and the error bars show the standard 
error of each time-point for both groups. In the lower panel it is shown the number of observation per year.
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DISCUSSION
Here we report the first published study to examine 
the influence of weight loss on cognitive decline and on 
AD CSF and imaging biomarkers in a large multicenter 
cohort of cognitively normal individuals. Our data support 
the hypothesis that unintentional weight loss in healthy 
elderly subjects is a non-cognitive sign of preclinical AD 
and demonstrate a significant association between weight 
loss and cognitive decline in healthy elderly subjects. 
Specifically, those subjects with significant weight loss 
presented an extra 0.57 points per year in ADAS-Cog 
score compared to those participants without weight loss. 
These data are in agreement with previously published 
epidemiological studies identifying weight-loss as a risk 
factor for incident MCI [7, 12, 13].
In contrast to a previous study [26], we also report 
an association between weight loss and increased AD 
biomarker levels. That being said, this discrepancy may 
be due to the inclusion of individuals with MCI and 
dementia in the previous study and that the BMI change 
was assessed as a continuous variable [26]. As mentioned 
in the methods section, this approach could have reduced 
sensitivity for detecting an association between weight 
loss and biomarker levels. Moreover, the previous study 
included fewer HC than this study. Our data are, however, 
in agreement with a previous autopsy study which found 
that AD plaque and tangle pathology was related to 
declining BMI in the years preceding death in demented 
and non-demented subjects [27].
We also describe an association between weight 
loss and baseline and longitudinal atrophy. Admittedly, 
in addition to AD-vulnerable areas, some of the clusters 
were found in areas atypical for AD. Therefore, we 
cannot exclude that, at least in part, other non-AD related 
neurodegenerative processes might contribute to weight 
loss and cognitive decline. This association between body 
Figure 3: Group comparison of the structural changes between the weight loss group (WLG) and non-weight loss 
group (non-WLG). A1. Baseline differences in cortical thickness between the weight loss group (WLG) and the non-weight loss group 
(non- WLG). Blue areas represent significant cortical thinning in the WLG respect to the non-WLG (FWE < 0.05). A2. Box and whisker 
plots showing the cortical thickness for each group at the maximum significant vertex in the right temporal cluster. B1. Differences in the 
symmetrized percent change (spc) over the 2-year follow-up between WLG and non-WLG. Blue indicates significant increased cortical 
atrophy (i.e., less spc) in the WLG (FWE < 0.05). B2. Box and whisker plots showing the symmetrized percent change for each group at 
the maximum significant vertex in the right frontal cluster. The colors in the box-plots are only for illustrative purposes. 
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weight changes and brain structure in HC has seldom been 
reported [28, 29]. Driscoll et al. in a large cohort of healthy 
elderly women found that a significant BMI decline (also 
defined as >5% of BMI from baseline to the last visit) in 
the years preceding the MRI scan (mean of 6.6 years) was 
cross-sectionally associated with reduced temporal grey 
matter volume and reduced volume of the cingulate cortex 
and hippocampus [29]. Similarly, in a longitudinal study, 
Bobb et al., found that weight loss over a five-year period 
was significantly associated with a decline in hippocampal 
volume, but this study did not find changes in the cortical 
mantle [28]. It may be pertinent that the mean age in that 
study was significantly younger than in the present study 
(60.1 vs. 74.9 years). 
Finally, it is noteworthy that the association between 
weight loss, AD biomarkers and brain atrophy in healthy 
ADNI participants remained significant even after the 
exclusion of subjects with progression to MCI or dementia 
in the follow-up, suggesting that weight loss starts early in 
preclinical AD stages.
The underlying mechanism that links weight loss 
to preclinical AD has yet to be elucidated but could be 
attributed to many factors. First, symptoms such as 
depression or anxiety, frequently observed during the 
prodromal (and preclinical) stages of AD, may affect 
appetite and energy intake. That being said, previous 
epidemiological studies show that the association between 
weight loss and incident dementia remains significant 
even after controlling for depressive symptomatology 
[30, 31]. Second, olfactory impairment has been observed 
in subjects with MCI and dementia and has been related 
to decreased hippocampus volume, thinner entorhinal 
cortex and greater amyloid burden in normal cognitive 
subjects [32]. Moreover, a recent study identified 
olfactory dysfunction as a predictor of amnestic MCI [33], 
suggesting that impaired olfaction is present very early in 
the AD continuum. Impaired olfaction may alter gustatory 
sensitivity and may thus influence food preferences and 
contribute to reduced calorie intake. Interestingly, previous 
studies have identified diminished gustatory sensitivity 
in both MCI and AD patients [34, 35]. Third, AD might 
affect the neuronal circuits involved in the regulation of 
eating behavior causing significant alterations in energy 
intake. Although homeostatic regulation of energy 
intake is located in the hypothalamus and brainstem, 
this homeostatic system is strongly influenced and 
could be overridden by hedonic signals. Hedonic eating 
is governed by the brain reward system, and the brain 
regions responsible of the reward system are dispersed in 
the corticolimbic structures [36]. In this respect, in animal 
studies the injection of β-amyloid into the hipoccampus 
caused reduced energy intake and decreased body weight 
[37, 38]. Finally, AD has also been associated to a 
hypermetabolic state which could explain the relationship 
with weight loss. In animal models overexpressing the APP 
gene, an increased energy expenditure without alterations 
in feeding behavior has been observed prior to plaque 
formation [39]. In humans, nonetheless, previous studies 
evaluating the total energy expenditure and its components 
(resting energy metabolism, diet induced thermogenesis 
and physical activity energy expenditure) did not reveal 
significant differences between subjects with or without 
AD dementia [40]; however energy expenditure has yet 
to be assessed in preclinical AD subjects. It is possible 
that these proposed mechanisms could occur individually 
or in combination and may change over the decades-long 
AD process.
Our results may have direct implications for clinical 
practice. First, unexplained weight loss in the healthy 
elderly could help to identify persons at-risk for MCI and 
AD dementia. Second, these data support the need for a 
careful nutritional evaluation in subjects with incident 
MCI or dementia, as poor nutritional status, loss of 
muscle mass and specific micronutrients deficits can be 
expected after a long period of negative energy balance. 
Finally, these results may be of relevance when assessing 
the relation between late-life obesity, AD biomarkers 
and AD risk and might help to explain the so called 
“obesity paradox”. Thus, although mid-life obesity has 
been consistently linked to AD and AD pathology [41], 
the relationship between late-life obesity and dementia is 
controversial [42]. Weight loss could be a confounding 
factor in this association. Further studies describing weight 
trajectories across the AD continuum are needed to better 
define the precise temporal association between preclinical 
AD and body weight changes.
Several limitations should be considered when 
interpreting the data reported here. Firstly, intentional 
weight loss cannot be differentiated from unintentional 
weight loss in the ADNI cohort. However, since previous 
studies have shown that intentional weight loss in healthy 
obese subjects and in obese MCI patients has beneficial 
cognitive effects [43-45], it is unlikely that the observed 
weight loss in our study was intentional. A further 
limitation is that we cannot specify the type of body 
composition changes or quantify physical activity levels 
[46, 47] since this information is not available in ADNI 
database. Third, subjects with significant weight loss 
had longer follow-up than subjects without weight loss. 
Nonetheless, differences were found in all biomarkers at 
baseline and the statistical methods employed were robust 
to differences in follow-up across groups. 
In conclusion, our data support that weight loss 
in healthy elderly is a non-cognitive sign of preclinical 
AD. Weight loss is related to faster cognitive decline, 
accelerated brain atrophy rates and is correlated with AD 
biomarker. The mechanisms involved in this association 
warrant further investigation.
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MATERIALS AND METHODS
Participants
Data used in the preparation of this article were 
obtained from the ADNI database (adni.loni.usc.edu). 
The ADNI was launched in 2003 by the National Institute 
on Aging (NIA), the National Institute of Biomedical 
Imaging and Bioengineering (NIBIB), the Food and Drug 
Administration (FDA), private pharmaceutical companies 
and non-profit
organizations, as a $60 million, 5-year public-
private partnership. The primary goal of ADNI has been 
to test whether serial magnetic resonance imaging (MRI), 
positron emission tomography (PET), other biological 
markers, and clinical and neuropsychological assessment 
can be combined to measure the progression of mild 
cognitive impairment (MCI) and early AD. Determination 
of sensitive and specific markers of very early AD 
progression is intended to aid researchers and clinicians to 
develop new treatments and monitor their effectiveness, as 
well as lessen the time and costs of clinical trials.
The Principal Investigator of this initiative is 
Michael W. Weiner, MD, VA Medical Center and 
University of California – San Francisco. ADNI is the 
result of efforts of many co-investigators from a broad 
range of academic institutions and private corporations, 
and subjects have been recruited from over 50 sites across 
the U.S. and Canada. The initial goal of ADNI was to 
recruit 800 subjects, which has since been broadened 
to include ADNI-GO and ADNI-2. To date these three 
protocols have recruited over 1500 adults, ages 55 to 90, 
to participate in the research, consisting of cognitively 
normal older individuals, people with early or late MCI, 
and people with early AD. The follow-up duration of each 
group is specified in the protocols for ADNI-1, ADNI-2 
and ADNI-GO. Subjects originally recruited for ADNI-1 
and ADNI-GO had the option to be followed in ADNI-
2. For up-to-date information, see http://adni-info.org/. 
We selected all cognitively healthy controls (HC) with 
available baseline and longitudinal anthropometric and 
cognitive data for a minimum follow-up period of 12 
months. After revision of the ADNI subjects table, and 
in order to exclude other causes associated with weight 
loss, we excluded subjects that had: cancer, heart failure, 
renal disease, liver disease, stroke, gastroesophageal reflux 
disease, Lyme disease, pulmonary disease or Barretts 
disease. There were no differences between ADNI-GO 
and ADNI2 with respect to the healthy controls inclusion 
criteria, the protocols of clinical follow-up, CSF measure, 
FBP PET or structural MRI acquisitions.
Clinical and cognitive data
Baseline demographic data (age, gender, 
education and Type 2 Diabetes (T2D) medication), 
neuropsychological performance, anthropometric data 
(height, weight, systolic and diastolic blood pressure) 
and laboratory data (fasting plasmatic glucose -FPG-, 
cholesterol, and triglycerides) were downloaded from the 
ADNI database. Diabetes status was assigned according 
to FPG ≥126 mg/dL (n = 20) and/or the use of glucose 
lowering agents (n = 22) [16]. Follow-up visits were 
conducted yearly. Data on body weight and ADAS-Cog 
score were downloaded from each subject at each follow-
up visit. We selected ADAS-Cog score 13 as measure of 
cognitive performance because it is the most widely used 
general cognitive measure in clinical trials of AD [17].
Assessment of body weight changes
Body weight change was expressed as relative 
weight change with respect to the weight at baseline 
[(follow-up weight – baseline weight) / baseline 
weight*100]. Relative body weight change was selected 
rather than total weight or BMI change in order to take 
into account baseline differences in body weight. Small 
changes of body weight can be due to measurement error, 
clothing, food consumption or fluid balance and may 
have little clinical relevance [18]. Therefore, following 
consensus criteria for wasting disease and current 
definition of meaningful weight loss [18, 19] the sample 
was categorized into two weight-change categories in the 
main analyses: Participants with relative weight loss ≥ 5% 
at last available follow-up were classified as weight loss 
group (WLG) whereas subjects with relative weight loss < 
5% were classified as non-weight loss group (non-WLG).
Genetic and CSF data
APOE genotype was determined at the ADNI 
Biomarker Core Laboratory. Participants were considered 
APOE ε4 positive (APOE4) if they carried at least one 
APOE ε4 allele. CSF biomarker values were obtained 
from the ADNI database. Two hundred and forty of 
363 participants (66.1%) included in the study had CSF 
available at baseline. Methods for CSF acquisition and 
analysis have been previously reported [20]. We used the 
ratio between t-tau and Aß42 (tau/Aß42 ratio) to evidence 
the AD pathophysiological process[15]. T-tau was used 
instead of p-tau because in ADNI, t-tau has a higher 
specificity than p-tau (92,3% vs 73,1%) [20].
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Amyloid PET acquisition and processing
One hundred and sixty five subjects of 363 (45.5%) 
had available AV45 PET scan at baseline. The details for 
AV45 PET scan acquisition are available elsewhere (http://
www.adni-info.org). Composite AV45 standardized uptake 
values ratios (SUVR) relative to the whole cerebellum 
were obtained from the ADNI database.
MRI acquisition and analysis
We selected those participants with available 3T 
MRI. The details of MRI acquisition and pre-processing 
are available elsewhere (http://adni-info.org/). All 
structural MRIs were first processed using the cross-
sectional cortical reconstruction stream in Freesurfer 
(v5.1;http://surfer.nmr.mgh.harvard.edu)[21, 22]. For the 
cross-sectional analyses, after excluding subjects with 
lack of CSF data (n = 34) and segmentation errors (n = 
33), 131 baseline MRI were included. Cortical thickness 
was calculated as the distance from the grey/white matter 
boundary closest to the grey/CSF boundary at each vertex.
The longitudinal analyses were performed with 
the Freesurfer longitudinal stream [23]. Specifically, 
an unbiased within-subject template space and image is 
created using all time-point MRIs available, including 
1-year follow-up (n = 57), for each subject [24]. After 
the exclusion of subjects with lack of baseline CSF 
data (n = 17), 104 were included in the longitudinal 
analyses. Symmetrized percent change (spc) values 
between baseline and two-year MRIs time-points were 
automatically extracted and introduced in the two stage 
model as implemented in Freesurfer [25]. Briefly, the spc 
measure is the annual rate of atrophy between two time-
points with respect to the average thickness between them. 
Finally, both measures (cortical thickness and spc maps) 
were smoothed using a Gaussian kernel of 15mm full-
width at half maximum.
Statistical analysis
Demographic, anthropometric and cognitive 
variables were compared across groups using student 
t-tests, and χ2 tests. Linear mixed-effects models using 
the Maximum Likelihood method for the change in 
the ADAS-Cog score were performed on the entire 
longitudinal database. In the primary analyses, weight 
variation was treated as a dichotomous variable (WLG and 
non-WLG). Intercept, age, sex, weight change-category, 
time from baseline and the interaction between time and 
weight change-category were included as covariates. 
Intercept and time from baseline were included as subject-
specific random effects. In the secondary analyses, weight 
changes were treated as a continuous variable (percentage 
with respect to baseline weight). Less than 10% of the 
cohort had a follow-up beyond 96 months. Therefore, 
the clinical analyses were censured at month 96. The 
sample size for each group and the observed mean (SEM) 
differences in ADAS-Cog13 at each visit were reported for 
each WL trajectory group. 
The associations between weight changes with both 
individual baseline CSF biomarkers and AV45-SUVR 
were tested both using analysis of covariance –ANCOVA– 
(primary analysis) and regression analyses (secondary 
analysis). Statistical significance was set at 5% (alpha level 
= 0.05). R software (version 3.2.5, www.r-project.org) and 
lme4 were used to perform the statistical analyses.
To study the association of CTh and spc with weight 
trajectories, group comparisons were performed between 
the WLG and the non-WLG (primary analyses) and 
correlation analyses (secondary analyses) using the QDEC 
tool in Freesurfer. We tested Monte-Carlo simulation with 
10,000 repeats as implemented in Qdec (family wise error 
[FWE] correction at p < 0.05). The figures show only 
those results that survived FWE correction.
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